1例视网膜母细胞瘤患儿多次全身化疗的远期安全性药学监护  

Pharmaceutical Care for Long-term Safety Multiple Chemotherapy in A Retinoblastoma Patient

作　　者：李英[1] 黄琳[2] 王晓玲[1] 

机构地区：[1]首都医科大学附属北京儿童医院药学部,北京100045 [2]北京大学人民医院药剂科,北京100044

出　　处：《中国药学杂志》2016年第13期1148-1151,共4页Chinese Pharmaceutical Journal

摘　　要：目的临床药师通过参与1例视网膜母细胞瘤(retinoblastoma,RB)患儿多次全身化疗的药学实践,探讨儿童化疗远期安全性的药学监护。方法临床药师根据患儿的实际情况,提供咨询意见和药学信息支持,梳理多次全身化疗的远期毒性,并进行全程药学监护。结果患儿顺利完成本次化疗,并接受建议前往寻求外科干预。结论多次全身化疗相关远期毒性可显著影响RB患儿生活质量,临床药师应加以关注和监护。OBJECTIVE To optimize the chemotherapy regimen for one pediatric patient with retinoblastoma. METHODS Clinical pharmacists provided advice to the physicians to develop targeted treatment programs and medication counseling to the patient＇s parents to improve the long-term safety of chemotherapy. RESULTS The patient finished this cycle of chemotherapy safely, and took the physicians advice to receive surgical therapy in the future. CONCLUSION Multiple chemotherapy-related long-term safety issues might significantly affect the future life of pediatric patients with retinoblastoma, which needs more attention.

关 键 词：视网膜母细胞瘤 儿童 化疗 远期安全性 药学监护 

分 类 号：R969.3[医药卫生—药理学]